



CRISPR/Cas9-mediated generation of a *Plac8* knockout mouse model

HyunJeong Lee^{1,#}, Joo-Il Kim^{2,3,#}, Jin-Sung Park³, Jae-il Roh^{1,*}, Jaehoon Lee^{1,*},
Byeong-Cheol Kang^{2,3,4,*}, Han-Woong Lee^{1,*}

¹Department of Biochemistry, College of Life Science and Biotechnology and Yonsei Laboratory Animal Research Center, Yonsei University, Seoul, Korea

²Graduate School of Translational Medicine, Seoul National University College of Medicine, Seoul, Korea

³Department of Experimental Animal Research, Biomedical Research Institute, Seoul National Univ. Hospital, Seoul, Korea

⁴Designed Animal and Transplantation Research Institute, Institute of GreenBio Science Technology, Seoul National University, Pyeongchang-gun, Korea

Placenta specific 8 (PLAC8, also known as ONZIN) is a multi-functional protein that is highly expressed in the intestine, lung, spleen, and innate immune cells, and is involved in various diseases, including cancers, obesity, and innate immune deficiency. Here, we generated a *Plac8* knockout mouse using the CRISPR/Cas9 system. The Cas9 mRNA and two single guide RNAs targeting a region near the translation start codon at *Plac8* exon 2 were microinjected into mouse zygotes. This successfully eliminated the conventional translation start site, as confirmed by Sanger sequencing and PCR genotyping analysis. Unlike the previous *Plac8* deficient models displaying increased adipose tissue and body weights, our male *Plac8* knockout mice showed rather lower body weight than sex-matched littermate controls, though the only difference between these two mouse models is genetic context. Differently from the previously constructed embryonic stem cell-derived *Plac8* knockout mouse that contains a neomycin resistance cassette, this knockout mouse model is free from a negative selection marker or other external insertions, which will be useful in future studies aimed at elucidating the multi-functional and physiological roles of PLAC8 in various diseases, without interference from exogenous foreign DNA.

Keywords: PLAC8, CRISPR/Cas9, mouse model

Received 15 November 2018; Revised version received 7 December 2018; Accepted 8 December 2018

Cancer, obesity, and innate immune deficiency are major diseases whose incidence has rapidly increased in recent years, leading to risings costs of treatment and deterioration of quality of life for those affected [10,37]. One protein that has been implicated to play a role in all

these conditions is PLAC8, a 12.5-kDa protein consisting of 112 amino acids, which is encoded by the *Plac8* gene and expressed primarily in epithelial and immune cells [9,22]. Specifically, a number of previous studies conducted using embryonic stem (ES) cell-based *Plac8*

[#]These authors contributed equally to this work

*Corresponding authors: Han-Woong Lee, Department of Biochemistry, College of Life Science & Biotechnology, Yonsei University, Seoul 03722, Korea

Tel: +82-2-2123-5698; Fax: +82-2-2123-8107; E-mail: hwl@yonsei.ac.kr

Byeong-Cheol Kang, Graduate School of Translational Medicine, Seoul National University College of Medicine, 101 Daehakro, Jongno-gu, Seoul 110-744, Korea

Tel: +82-2-2072-0841; Fax: +82-2-741-7620; E-mail: bckang@snu.ac.kr

Jaehoon Lee, Department of Biochemistry, College of Life Science & Biotechnology, Yonsei University, Seoul 03722, Korea

Tel: +82-2-2123-7642; Fax: +82-2-2123-8107; E-mail: jhlee13@gmail.com

Jae-il Roh, Department of Biochemistry, College of Life Science & Biotechnology, Yonsei University, Seoul 03722, Republic of Korea

Tel: +82-2-2123-7642; Fax: +82-2-2123-8107; E-mail: rohjaeil@gmail.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

knockout (KO) mouse models have reported the involvement of *PLAC8* in colorectal and pancreatic cancer progression [16,19,24], irregular differentiation of brown/white fat cells [13,15], and innate immune deficiency due to various mechanisms [22].

Colorectal and pancreatic cancers are devastating diseases that show poor survival rates due to a low incidence of early stage detection, rapid metastasis, and poor response to therapeutics [26,27]. Numerous genetic studies have reported frequent mutations in the *KRAS* and *TP53* genes in colorectal and pancreatic cancers, which promote strong invasiveness *via* the epithelial to mesenchymal transition (EMT) [2,3,17,25]. Notably, it was found that *PLAC8* accelerates tumorigenesis and metastasis by promoting cell growth in the RAS and TP53 mutant types of pancreatic and colorectal cancers [16,19]. In addition, invasiveness and tumor size are increased by *PLAC8* upregulation through the activation of extracellular signal-regulated kinase 2 (ERK2) in colorectal cancer [24]. Obesity, which afflicts approximately 13% of individuals worldwide [20], is characterized by excessive fat tissue that is associated with an increase in both adipocyte number and size [7]. *PLAC8* has further been shown to modulate the morphology and thermogenic ability of brown adipocytes by acting as a novel upstream regulator of CCAAT/Enhancer binding protein β (C/EBP β). Loss of *PLAC8* also increases the size of white adipocytes through the induction of the early growth response 2 (EGR2/KROX20) and kinesin family member 4 (KIF4) proteins, which are the early regulators of white adipogenesis [13,15]. The innate immune response is a major host defense system that recognizes, attacks, and eliminates foreign and infectious substances from the body [21]. Neutrophils, the most abundant cell type in the innate immunity, recognize various pathogens and control immune responses, mainly by chemotaxis and phagocytosis [6,11,33,36]. *PLAC8* has been implicated in neutrophil function, and a *Plac8* KO impairs host defense activity by accelerating apoptosis and reducing phagocytic ability of neutrophils [22]. Collectively, these findings highlight the potential utility of an unmarked *Plac8* KO mouse model for the investigation of tumorigenesis, adipogenesis, and innate immunity.

Engineered nucleases have been utilized to generate a number of rapidly developing tools for genome editing [4]. A system of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (Cas) proteins is the third-generation of an engineered

endonuclease, containing a guide RNA and Cas protein, which efficiently introduces DNA double-strand breaks at a target site, leading to non-homologous end joining (NHEJ)-mediated DNA repair [38]. Compared with conventional gene targeting strategies in ES cells, methods using CRISPR/Cas systems enable the manipulation of genes at the single nucleotide level and show increased efficiency for establishing animal models, mimicking human disease phenotypes, in a short period of time [29]. Here, to avoid any conflicts caused by patents or primary authority, we generated a new *Plac8* KO mouse model that does not harbor a negative selection marker, such as the neomycin resistance (*Neo^R*), using the CRISPR/Cas9 system. We expect that this model will help to further elucidate the myriad of roles that *PLAC8* plays in human disease.

Materials and Methods

In vitro synthesis of single guide RNAs and Cas9 mRNA

Cas9 mRNA and single guide RNAs (sgRNAs) were synthesized as described previously [5,34]. Briefly, *Cas9* mRNA was prepared *in vitro* from linear DNA templates, using the mMACHINE T7 Ultra Transcription Kit (Invitrogen, Carlsbad, CA, USA), and sgRNAs were generated using the MEGashortscript T7 Transcription Kit (Invitrogen), both according to the manufacturer's instructions. The following sequences were used for sgRNA synthesis: left sgRNA, TTGAGACCTCGCATCGAAGATGG; right sgRNA, TGTGATTGCTTCAGTACTGCGG.

Generation and maintenance of *Plac8* KO mice

Plac8 KO mice were generated using the CRISPR/Cas9 system, as described previously [32]. In brief, *Cas9* mRNA and sgRNAs were microinjected into fertilized embryos of C57BL/6J mice. Mutations in *Plac8* were confirmed by Sanger sequencing analyses (BIONICS Ltd., Korea). Homozygous KO mice were born from a heterozygous intercross and used for phenotypic analyses in parallel with age- and sex-matched wild-type (WT) littermates as a control group. All mice were genotyped 2 weeks after birth, using PCR with specific primers (forward, 5'-GCAACTTTCCACACAGTAAG-3' and reverse, 5'-GCACAGCAGGTAGGGCTAAC-3'), and animals were housed according to their gender after weaning. Mice were kept in an enriched environment

under the standard conditions (22±2°C temperature, 40-60% humidity) with a 12 h light/dark cycle at the Specific-Pathogen-Free (SPF) facility [18]. During the experiment period, mice were given free access to food (Lab-Diet 5002 Certified Rodent Diet, PMI Nutrition International, St. Louis, MO, USA) and water. All experiments in this study were approved by the Institutional Animal Care and Use Committees at Yonsei University and Seoul National University Hospital. Animals were maintained in accordance with Guide for the Care and Use of Laboratory Animals, 8th edition, National Research Council (2010).

RNA isolation and Real-time quantitative PCR (RT-qPCR)

Total RNA was extracted from the intestine, liver, heart, lung, and brown adipose tissues (BAT) of each mouse using TRIzol reagent (Invitrogen) as described previously [31]. Subsequently, cDNA was synthesized using a RevertAid First strand cDNA Synthesis Kit (Thermo Fisher Scientific). Real-time quantitative PCR was performed in the triplicate using CFX (Bio-Rad) [30] with following primers; *Plac8*, 5'-GTCTTGGATG TCAAGTGGCAGC-3' (forward) and 5'-CAGGACAG AAGAGTGTGACCATG-3' (reverse); and *Gapdh*, 5'-CATCACTGCCACCCAGAAGACTG-3' (forward) and 5'-ATGCCAGTGAGCTTCCCGTTCAG-3' (reverse).

Measurement of physiological parameters: body weight gain, food, and water consumption

The main physiological parameters of *Plac8* KO mice and their WT littermates were monitored from 4 to 52 weeks of age. During that time period, body weight and both food and water consumption were measured once a week, with daily observation of clinical signs. Food and water consumption were calculated as the amount of intake per mouse for 24 h. All experiments were conducted during the light cycle with gentle handling, so as to minimize stress on the animals. The raw data are available on request.

Hematology, serum biochemistry, urinalysis, and organ weight measurement

All mice were sacrificed by anesthetizing with isoflurane and exsanguination at 52 weeks of age. Whole blood was collected from the inferior vena cava in K2EDTA-containing tubes (BD Microtainer, Becton Dickinson, Franklin Lakes, NJ, USA) and analyzed using the

ADVIA 2120i Hematology System (SIEMENS Healthineers, Erlangen, Germany) for determination of the following parameters: total and differential white blood cell, red blood cell (RBC), platelet (PLT), hemoglobin (HGB), and hematocrit (HCT) counts, as well as mean corpuscular volume, mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC). In serum, the levels of blood urea nitrogen, total cholesterol, total protein, total bilirubin, aspartate transaminase (AST), alkaline phosphatase (ALP), alanine transaminase (ALT), γ -GT, albumin, creatinine, triglyceride (TG), glucose, albumin/globulin (A/G) ratio, potassium, chloride, sodium, and phosphorus were measured with a Hitachi 7070 Chemistry Analyzer (Hitachi, Japan). Urine collected from each mouse was applied to a urine stick (Multistick 10 SG, SIEMENS) and analyzed using an automatic urinalysis machine (CLINITEK Advantus Urine Chemistry Analyzer, SIEMENS) for measurement of leukocytes, nitrite, urobilinogen, protein, pH, blood, specific gravity, ketones, bilirubin, and glucose. The weight and gross morphological changes of all organs were examined after exsanguination. Testis and epididymis were preserved in Bouin's solution, and Harderian glands and eyes were fixed in Davidson solution. All other organs were fixed in 10% neutral buffered formalin.

Statistical analysis

All values are expressed as the mean±standard deviation (SD). Statistical analysis was carried out using Welch's t-test in SPSS software, version 22.0 (SPSS Inc., Chicago, IL, USA). *P*-values <0.05 were regarded as statistically significant.

Results

Establishment of a *Plac8* KO mouse model by CRISPR/Cas9 microinjection

To construct a *Plac8* KO mouse model, we designed sgRNAs targeting the translation start codon in exon 2 of the *Plac8* gene [8,12]. These were delivered to mouse embryos by microinjection together with *Cas9* mRNA, and *Plac8* gene mutations were screened by PCR, using primers spanning the target sites; KOs were confirmed by Sanger sequencing analyses (Figure 1A). The chosen mouse line harbors a 99 bp deletion mutation, abolishing the conventional translational start site (Figure 2A), and genotypes were confirmed by PCR genotyping (Figure 1B). We note that this 99 bp difference was sufficient to




Figure 1. CRISPR/Cas9-mediated generation of a *Plac8* KO mouse model. (A) A representative view of the CRISPR/Cas9 targeting strategy used for generating *Plac8* knockout (KO) mice. The nucleotide and amino acid (in purple) sequences of wild-type (WT) and KO alleles are shown. Exons are indicated with black and gray boxes, and introns are noted by black lines. The targeting sites are indicated by yellow arrows, and the binding sites for single guide RNAs (sgRNAs) are marked in blue, with the protospacer adjacent motif (PAM) sequence in red. The conventional start codon (ATG) is indicated in green. (B) A representative PCR genotyping result for *Plac8* WT, homozygous (KO), and heterozygous (Het) KO mice. (C) Relative *Plac8* mRNA levels in the intestine, liver, heart, lung, and brown adipose tissue (BAT) of the *Plac8* KO (Black bar) mice were compared to WT (White bar). The mRNA levels were normalized by *Gapdh*. Graph shows mean ± standard deviation.

distinguish PCR products from WT and KO mice. Analysis of *Plac8* transcript level by RT-qPCR showed the impaired *Plac8* expression in the intestine, liver, heart, lung, and brown adipose tissues of the *Plac8* KO, compared to control mice (Figure 1C). Compared with previously generated *Plac8* KO mice, in which exon 4 was replaced with the *Neo^r* cassette, our newly established *Plac8* KO mouse model targets an upstream region (exon 2) and contains no selectable marker.

Characterization of basic phenotypes in *Plac8* KO mice

To characterize the basic phenotypes of *Plac8* KO mice, physiological parameters, including genotype and sex ratio at birth, as well as whole body and organ weight gain were examined. The sex ratio of pups born from *Plac8* heterozygous knockout (HT) parents was 1:0.9 (male, n=56; female, n=51), whereas the genotype ratio of siblings was 1:2.1:0.6, for WT, HT, and KO, respectively. These data suggest that *Plac8* KO does not affect gender determination, although the genotype birth ratio may warrant further investigation. As the previous

Plac8 KO mouse exhibited increased adipose tissue weight, we expected the augmentation of body or tissue size and weight in our *Plac8* KO mouse model. However, male *Plac8* KO mice showed lower body weight compared to their WT littermates over the entire observation period, with significant differences observed between 29 to 44 weeks of age, excepting for week 30 (Figure 2A and Table 1). Conversely, the body weights of female mice were comparable between the two groups (Figure 2A). Because dietary intake is a major factor for body weight gain, food and water consumptions were monitored throughout the experimental time period, and we found no intake differences in *Plac8* KO mice, as compared with their WT littermates (Figures 2B and C). Additionally, consistent with previously reported data, no significant changes were observed in any of the other organs (Table 1) [22], although marginal differences were noted in some.

Hematology, serum biochemistry, and urinalysis in *Plac8* KO mice

Analysis of whole blood revealed that RBC, HCT, and




Figure 2. Measurement of physiological parameters in *Plac8* KO mice and comparison to WT littermate controls. (A and B) Body weight changes in *Plac8* WT and KO of male (A) and female (B) mice from 4 to 52 weeks of age. (C-F) The amount of daily food (C and D) and water (E and F) consumed by WT and *Plac8* KO male (C and E) and female (D and F) mice from 4 to 52 weeks of age. WT animals are shown in white dots, and KO mice are shown in black dots. Male mice are indicated with squares (A, C, and E), and female mice are indicated with circles (B, D, and F). Graphs show mean \pm standard deviation. * $P < 0.05$.

PLT counts were increased, whereas MCH and MCHC were decreased in 52-week-old female KO mice, as compared to age and sex-matched WT littermate controls (Table 2). In contrast, all other parameters were comparable between WT and KO mice, except for a decreased population of monocytes in male KO mice vs. controls. Serum biochemistry and urinalysis revealed no changes in *Plac8* KO mice compared to their WT littermates (Tables 3 and 4).

Discussion

In this study, we used the CRISPR/Cas9 system to generate an unmarked *Plac8* KO mouse line. Macroscopic examinations showed no gross differences in organ size and weight, blood cell counts, serum biochemistry, or urinalysis in KO mice compared to sex-matched WT littermates, although minimal alterations, such as in body weight, were detected in some KO animals under normal conditions. Notably, an observation in the previous *Plac8* KO mouse that displays increased weight of whole body and adipose tissues [13,14] is an opposite tendency to our *Plac8* KO mouse model. It is unclear

why there are phenotypic differences between our model and the previously generated model that showed obese phenotype [13], but some possibilities include the distinct targeting loci used in each KO, the presence of the *Neo^R* cassette in the previous model, and mouse background [28,39]. Further examinations are required to reveal the phenotypic differences between the previous and our *Plac8* KO mouse models. In addition, there is a possibility of unexpected expression of truncated *Plac8* protein through an alternative translation by the other in-frame ATG site in exon 3 and 4. As a considerable quantity of *Plac8* transcript was detected in the lung and BAT of *Plac8* KO mouse, further experiments are required to decide the probable expression of truncated PLAC8 protein in that tissues.

Screening of ES cells with the positive selection reagent, geneticin (G418), is a convenient method for detecting targeted ES cell lines containing the *Neo^R* cassette and has been successfully applied in many instances for KO mouse generation. Despite these results, possible undesirable effects due to the *Neo^R* gene should be considered for improvement of current animal models. For instance, insertion of this gene silences the

Table 1. Absolute and relative organ weight in 52-week-old *Plac8* KO mice

Organ		WT male	KO male	WT female	KO female
		(n=9)	(n=7)	(n=10)	(n=8)
Body weight	(g)	37.50±3.00	33.74±3.86	30.01±5.12	30.66±7.26
Liver	(g)	1.57±0.26	1.41±0.13	1.21±0.20	1.29±0.33
	(g%)	4.20±0.80	4.23±0.59	4.03±0.24	4.22±0.48
Spleen	(g)	0.09±0.03	0.09±0.02	0.10±0.02	0.09±0.02
	(g%)	0.24±0.09	0.28±0.09	0.33±0.07	0.30±0.05
Kidney (right)	(g)	0.19±0.03	0.17±0.02	0.15±0.03	0.14±0.02
	(g%)	0.51±0.07	0.52±0.09	0.50±0.08	0.49±0.09
Kidney (left)	(g)	0.18±0.02	0.17±0.02	0.14±0.02	0.14±0.03
	(g%)	0.49±0.07	0.51±0.09	0.47±0.06	0.47±0.08
Adrenal gland (right)	(g)	0.0013±0.0006	0.0014±0.0004	0.0027±0.0007	0.0028±0.0009
	(g%)	0.0036±0.0015	0.0042±0.0011	0.0091±0.0022	0.0096±0.0038
Adrenal gland (left)	(g)	0.0014±0.0005	0.0017±0.0004	0.0031±0.0004	0.0034±0.0005
	(g%)	0.0038±0.0016	0.0050±0.0011	0.0107±0.0022	0.0116±0.0029
Testis (right)	(g)	0.0939±0.0194	0.1031±0.0094	0.0018±0.0012	0.0036±0.0020
Ovary (right)	(g%)	0.25±0.05	0.31±0.05*	0.0057±0.0030	0.0034±0.0023*
Testis (left)	(g)	0.09±0.02	0.11±0.02	0.0014±0.0010	0.0034±0.0023
Ovary (left)	(g%)	0.25±0.05	0.33±0.06	0.0049±0.0038	0.0123±0.0083
Thymus	(g)	0.0266±0.0053	0.0290±0.0068	0.0317±0.0065	0.0424±0.0108
	(g%)	0.0709±0.0133	0.0886±0.0300	0.1071±0.0234	0.0116±0.0029*
Heart	(g)	0.16±0.01	0.16±0.02	0.13±0.02	0.11±0.05
	(g%)	0.43±0.05	0.48±0.10	0.44±0.05	0.37±0.15
Lung	(g)	0.16±0.01	0.21±0.13	0.16±0.01	0.19±0.10
	(g%)	0.43±0.04	0.66±0.50	0.53±0.08	0.62±0.29
Brain	(g)	0.46±0.01	0.47±0.02	0.48±0.02	0.49±0.01
	(g%)	1.24±0.11	1.39±0.17	1.65±0.27	1.66±0.35

P*<0.05 in comparison to respective gender-matching WT miceTable 2.** Hematological analysis in 52-week-old *Plac8* WT and KO mice

Parameters	WT male	KO male	WT female	KO female
	(n=9)	(n=7)	(n=10)	(n=7)
WBC (10 ³ /mm ³)	2.46±1.22	4.52±2.85	2.48±0.92	4.03±3.28
RBC (10 ⁶ /mm ³)	8.47±0.64	8.47±0.85	9.01±0.42	9.60±0.48*
HGB (g/dL)	12.4±0.5	12.2±1.2	13.4±0.5	13.6±0.8
HCT (%)	43.3±3.0	43.5±4.4	45.9±1.6	51.2±2.3**
PLT (10 ³ /mm ³)	1137±259	963±421	856±218	1129±146**
MCV (fl)	51.2±1.5	51.4±2.2	51.0±1.6	53.4±2.6
MCH (pg)	14.7±0.8	14.4±0.7	14.9±0.5	14.1±0.3**
MCHC (g/dL)	28.6±1.6	28.0±0.7	29.2±0.4	26.5±1.3**
Neutrophils (%)	18.3±8.5	15.2±8.5	11.6±2.7	17.2±1.3
Eosinophils (%)	2.2±1.0	1.6±1.0	5.6±8.1	2.2±1.9
Basophils (%)	0.3±0.2	0.2±0.2	0.4±0.3	1.3±1.0
Lymphocytes (%)	76.2±9.7	81.3±9.1	80.4±9.1	77.5±8.3
Monocytes (%)	1.4±0.9	0.3±0.3*	0.8±0.5	1.1±0.4
Reticulocytes (%)	4.21±0.70	5.18±3.16	4.41±0.63	3.87±0.63

P*<0.05 and *P*<0.01 in comparison to respective gender-matching WT mice

proximal promoters by five- to ten-fold, regardless of the orientation [1]. Further, *Neo^R* expression can render the cells less glycolytic and change the expressions of genes, such as *procollagen 1α*, *fibronectin*, and *C-MYC* [35].

Thus, our newly established *Plac8* KO model may more clearly show the *in vivo* function of *Plac8*, free from the off-target effects of the *Neo^R* gene.

We note, however, that in our model, it is unclear

Table 3. Serum biochemistry in 52-week-old *Plac8* WT and KO mice

Parameters	WT male	KO male	WT female	KO female
	(n=10)	(n=7)	(n=10)	(n=9)
BUN (mg/dL)	21.5±5.5	17.3±5.0	18.3±1.7	26.0±7.7
TC (mg/dL)	106±24	113±12	101±12	98±12
TP (g/dL)	4.6±0.4	4.5±0.4	4.7±0.3	4.8±0.4
Albumin (g/dL)	1.6±0.1	1.6±0.1	1.7±0.1	1.7±0.1
TB (mg/dL)	0.10±0.08	0.06±0.02	0.07±0.04	0.03±0.04
ALP (IU/L)	238±35	215±51	338±114	285±68
AST (IU/L)	68±27	77±24	91±71	118±46
ALT (IU/L)	42±29	41±19	33±17	54±30
GT (IU/L)	0±0	0±0	0.6±3.0	0±1
Creatinine (mg/dL)	0.31±0.09	0.32±0.05	0.32±0.08	0.36±0.07
TG (mg/dL)	25±16	25±13	22±12	38±21
Glucose (mg/L)	221±54	203±52	241±32	220±71
A/G	0.6±0.1	0.5±0.1	0.6±0.1	0.5±0.1
K (mEq/L)	4.5±0.3	4.3±0.4	4.3±0.5	4.8±0.6
Cl (mEq/L)	112±3	110±2	111±3	109±3
Na (mEq/L)	153±4	153±4	149±8.9	149±4
Ca (mg/L)	8.6±0.2	8.8±0.3	8.9±0.3	9.0±0.5
IP (mg/L)	6.6±1.7	6.5±1.3	6.8±1.0	8.0±2.8

Table 4. Urinalysis in 52-week-old *Plac8* WT and KO mice

		WT Male	KO Male	WT Female	KO Female
		(n=8)	(n=6)	(n=7)	(n=7)
Specific gravity	1.010	0	1	0	0
	1.020	0	0	1	0
	1.025	1	2	2	2
	≥1.030	7	3	4	5
Glucose (mg/dL)	negative	8	5	6	5
	100	0	1	1	2
Bilirubin	negative	6	5	2	4
	small	2	1	4	3
	moderate	0	0	1	0
Ketone (mg/dL)	negative	4	2	3	1
	trace	3	3	2	3
	15	1	1	2	3
Blood	negative	7	6	6	7
	trace-lysed	0	0	1	0
	moderate	1	0	0	0
pH		6.0	6.2	6.5	7.0
Protein (mg/dL)	negative	2	2	2	1
	trace	3	3	4	5
	30	3	0	1	1
	100	0	1	0	0
Urobilinogen (E.U./dL)		0.2	0.2	0.2	0.2
Nitrite	negative	8	6	7	7
Leucocytes	negative	7	4	6	7
	trace	1	2	1	0

whether the lack of a conventional translation start site allows the mutant mRNA to use an alternative ATG codon for translation initiation. However, in this event, the alternative translation would lead to a premature termination codon (PTC) 12 bp downstream of the ATG site, resulting in the probable synthesis of a peptide that is only five amino acids. In contrast, the WT protein is 112 amino acids. We would also expect this truncated mutant transcript to be eliminated by PTC-triggered nonsense-mediated mRNA decay [23].

In conclusion, PLAC8 is a multi-functional protein that is associated with a number of important diseases, such as cancer, obesity, and immune deficiency, that continue to adversely affect large numbers of people but remain incompletely understood [6,15,25]. In addition to the features indicated above, international mouse phenotyping consortium (IMPC) described novel phenotypes of *Plac8* KO mouse such as abnormal lens morphology, cataract, abnormal coat appearance, and decrease grip strength (<http://www.mousephenotype.org>). Based on our and IMPC results, we expect that our unmarked *Plac8* KO mouse model, generated using the CRISPR/Cas9 system, will be an important resource for fundamental research into these conditions, as well as for the development of therapeutics. The mouse model is available at the Korea Ministry of Food & Drug Safety (www.nifds.go.kr).

Acknowledgments

This work was supported by the National Research Foundation of the Republic of Korea (grants 2015R1A2A1A01003845 and 2017R1A4A1015328) and the Korea's Ministry of Food and Drug Safety (MFDS, 14182MFDS978).

Conflict of interests The authors declare that there is no financial conflict of interests to publish these results.

References

1. Artelt P, Grannemann R, Stocking C, Friel J, Bartsch J, Hauser H. The prokaryotic neomycin-resistance-encoding gene acts as a transcriptional silencer in eukaryotic cells. *Gene* 1991; 99(2): 249-254.
2. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rومان I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N; Australian Pancreatic Cancer Genome Initiative, Kakkar N, Zhao F, Wu YQ, Wang M, Muzny DM, Fisher WE, Brunicardi FC, Hodges SE, Reid JG, Drummond J, Chang K, Han Y, Lewis LR, Dinh H, Buhay CJ, Beck T, Timms L, Sam M, Begley K, Brown A, Pai D, Panchal A, Buchner N, De Borja R, Denroche RE, Yung CK, Serra S, Onetto N, Mukhopadhyay D, Tsao MS, Shaw PA, Petersen GM, Gallinger S, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Capelli P, Corbo V, Scardoni M, Tortora G, Tempero MA, Mann KM, Jenkins NA, Perez-Mancera PA, Adams DJ, Largaespada DA, Wessels LF, Rust AG, Stein LD, Tuveson DA, Copeland NG, Musgrove EA, Scarpa A, Eshleman JR, Hudson TJ, Sutherland RL, Wheeler DA, Pearson JW, McPherson JD, Gibbs RA, Grimmond SM. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature* 2012; 491(7424): 399-405.
3. Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, Kirchner T. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. *Cells Tissues Organs* 2005; 179(1-2): 56-65.
4. Brouns SJ, Jore MM, Lundgren M, Westra ER, Slijkhuis RJ, Snijders AP, Dickman MJ, Makarova KS, Koonin EV, van der Oost J. Small CRISPR RNAs guide antiviral defense in prokaryotes. *Science* 2008; 321(5891): 960-964.
5. Choi JY, Yun WB, Kim JE, Lee MR, Park JJ, Song BR, Kim HR, Park JW, Kang MJ, Kang BC, Lee HW, Hwang DY. Successful development of squamous cell carcinoma and hyperplasia in RGEN-mediated p27 KO mice after the treatment of DMBA and TPA. *Lab Anim Res* 2018; 34(3): 118-125.
6. Choy MC, Visvanathan K, De Cruz P. An Overview of the Innate and Adaptive Immune System in Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2017; 23(1): 2-13.
7. Couillard C, Mauriège P, Imbeault P, Prud'homme D, Nadeau A, Tremblay A, Bouchard C, Després JP. Hyperleptinemia is more closely associated with adipose cell hypertrophy than with adipose tissue hyperplasia. *Int J Obes Relat Metab Disord* 2000; 24(6): 782-788.
8. Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. *Nat Biotechnol* 2016; 34(2): 184-191.
9. Galaviz-Hernandez C, Stagg C, de Ridder G, Tanaka TS, Ko MS, Schlessinger D, Nagaraja R. Plac8 and Plac9, novel placental-enriched genes identified through microarray analysis. *Gene* 2003; 309(2): 81-89.
10. Gukovsky I, Li N, Todoric J, Gukovskaya A, Karin M. Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer. *Gastroenterology* 2013; 144(6): 1199-1209.
11. Hickey MJ, Kubes P. Intravascular immunity: the host-pathogen encounter in blood vessels. *Nat Rev Immunol* 2009; 9(5): 364-375.
12. Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li Y, Fine EJ, Wu X, Shalem O, Cradick TJ, Marraffini LA, Bao G, Zhang F. DNA targeting specificity of RNA-guided Cas9 nucleases. *Nat Biotechnol* 2013; 31(9): 827-832.
13. Jimenez-Preitner M, Berney X, Thorens B. Plac8 is required for white adipocyte differentiation in vitro and cell number control in vivo. *PLoS One* 2012; 7(11): e48767.
14. Jimenez-Preitner M, Berney X, Uldry M, Vitali A, Cinti S, Ledford JG, Thorens B. Plac8 is an inducer of C/EBP β required

- for brown fat differentiation, thermoregulation, and control of body weight. *Cell Metab* 2011; 14(5): 658-670.
15. Jimenez-Preitner M, Berney X, Uldry M, Vitali A, Cinti S, Ledford JG, Thorens B. *Plac8* is an inducer of C/EBP β required for brown fat differentiation, thermoregulation, and control of body weight. *Cell Metab* 2011; 14(5): 658-670.
 16. Kaistha BP, Lorenz H, Schmidt H, Sipos B, Pawlak M, Gierke B, Kreider R, Lankat-Buttgereit B, Sauer M, Fiedler L, Krattenmacher A, Geisel B, Kraus JM, Frese KK, Kelkenberg S, Giese NA, Kestler HA, Gress TM, Buchholz M. *PLAC8* Localizes to the Inner Plasma Membrane of Pancreatic Cancer Cells and Regulates Cell Growth and Disease Progression through Critical Cell-Cycle Regulatory Pathways. *Cancer Res* 2016; 76(1): 96-107.
 17. Kang Y, Massagué J. Epithelial-mesenchymal transitions: twist in development and metastasis. *Cell* 2004; 118(3): 277-279.
 18. Kim JH, Cho EY, Kwon E, Kim WH, Park JS, Lee YS, Yun JW, Kang BC. Gold thread implantation promotes hair growth in human and mice. *Lab Anim Res* 2017; 33(4): 291-297.
 19. Kinsey C, Balakrishnan V, O'Dell MR, Huang JL, Newman L, Whitney-Miller CL, Hezel AF, Land H. *Plac8* links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression. *Cell Rep* 2014; 7(4): 1143-1155.
 20. Krzizek EC, Brix JM, Herz CT, Kopp HP, Scherthaner GH, Scherthaner G, Ludvik B. Prevalence of Micronutrient Deficiency in Patients with Morbid Obesity Before Bariatric Surgery. *Obes Surg* 2018; 28(3): 643-648.
 21. Lachmann PJ. Microbial subversion of the immune response. *Proc Natl Acad Sci U S A* 2002; 99(13): 8461-8462.
 22. Ledford JG, Kovarova M, Koller BH. Impaired host defense in mice lacking *ONZIN*. *J Immunol* 2007; 178(8): 5132-5143.
 23. Lee JH, Rho JI, Devkota S, Sung YH, Lee HW. Developing genetically engineered mouse models using engineered nucleases: Current status, challenges, and the way forward. *Drug Discov Today: Disease Models* 2016; 20: 13-20.
 24. Li C, Ma H, Wang Y, Cao Z, Graves-Deal R, Powell AE, Starchenko A, Ayers GD, Washington MK, Kamath V, Desai K, Gerdes MJ, Solnica-Krezel L, Coffey RJ. Excess *PLAC8* promotes an unconventional ERK2-dependent EMT in colon cancer. *J Clin Invest* 2014; 124(5): 2172-2187.
 25. McMurray HR, Sampson ER, Compitello G, Kinsey C, Newman L, Smith B, Chen SR, Klebanov L, Salzman P, Yakovlev A, Land H. Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. *Nature* 2008; 453(7198): 1112-1116.
 26. Michl P, Gress TM. Current concepts and novel targets in advanced pancreatic cancer. *Gut* 2013; 62(2): 317-326.
 27. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. *CA Cancer J Clin* 2016; 66(4): 271-289.
 28. Müller U. Ten years of gene targeting: targeted mouse mutants, from vector design to phenotype analysis. *Mech Dev* 1999; 82(1-2): 3-21.
 29. Paquet D, Kwart D, Chen A, Sproul A, Jacob S, Teo S, Olsen KM, Gregg A, Noggle S, Tessier-Lavigne M. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. *Nature* 2016; 533(7601): 125-129.
 30. Roh JI, Cheong C, Sung YH, Lee J, Oh J, Lee BS, Lee JE, Gho YS, Kim DK, Park CB, Lee JH, Lee JW, Kang SM, Lee HW. Perturbation of *NCOA6* leads to dilated cardiomyopathy. *Cell Rep* 2014; 8(4): 991-998.
 31. Roh JI, Kim Y, Oh J, Kim Y, Lee J, Lee J, Chun KH, Lee HW. Hexokinase 2 is a molecular bridge linking telomerase and autophagy. *PLoS One* 2018; 13(2): e0193182.
 32. Roh JI, Lee J, Park SU, Kang YS, Lee J, Oh AR, Choi DJ, Cha JY, Lee HW. CRISPR-Cas9-mediated generation of obese and diabetic mouse models. *Exp Anim* 2018; 67(2): 229-237.
 33. Segal AW. How neutrophils kill microbes. *Annu Rev Immunol* 2005; 23: 197-223.
 34. Sung YH, Kim JM, Kim HT, Lee J, Jeon J, Jin Y, Choi JH, Ban YH, Ha SJ, Kim CH, Lee HW, Kim JS. Highly efficient gene knockout in mice and zebrafish with RNA-guided endonucleases. *Genome Res* 2014; 24(1): 125-131.
 35. Valera A, Perales JC, Hatzoglou M, Bosch F. Expression of the neomycin-resistance (*neo*) gene induces alterations in gene expression and metabolism. *Hum Gene Ther* 1994; 5(4): 449-456.
 36. Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P, Halbwachs-Mecarelli L. Neutrophils: molecules, functions and pathophysiological aspects. *Lab Invest* 2000; 80(5): 617-653.
 37. Wright C, Simone NL. Obesity and tumor growth: inflammation, immunity, and the role of a ketogenic diet. *Curr Opin Clin Nutr Metab Care* 2016; 19(4): 294-299.
 38. Wu X, Kriz AJ, Sharp PA. Target specificity of the CRISPR-Cas9 system. *Quant Biol* 2014; 2(2): 59-70.
 39. Yoshiki A, Moriwaki K. Mouse phenome research: implications of genetic background. *ILAR J* 2006; 47(2): 94-102.